17 completed, 9 unknown, 3 recruiting, 2 not yet recruiting. 14 Phase 4, 5 Phase 2, 4 Phase 1, 1 Early Phase 1, 1 Not applicable.
Follow velpatasvir: new trials by email Literature Review of velpatasvir trials Research Report on velpatasvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combating Related Epidemics in HCV Cepheid GeneXpert HCV Test, Abbott Determine HIV - 1/2 Ag/Ab, Abbott Determine HbsAg 2 - HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV) | Phase 4 | Not yet recruiting | Duke University | 1280 | 2027-01-20 | 2026-10-15 |
| AI-Powered Hepatitis C Single-Encounter Test-and-Treat Epclusa (sofosbuvir and velpatasvir) - HEPATITIS C (HCV) | Phase 4 | Not yet recruiting | Patrick Grace | 35 | 2026-12-01 | 2026-08-28 |
| Implementing Low-Barrier HCV Treatment in a Jail Setting Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Community Health Worker - HEPATITIS C (HCV), Incarceration | Phase 4 | Recruiting | Lifespan | 40 | 2025-06-11 | 2026-02-27 |
| Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and Tanzania sofosbuvir/velpatasvir (SOF/VEL), Shortened read time of rapid diagnostic test for hepatitis C virus. - Hepatitis C, RDT | Early Phase 1 | Recruiting | Médecins du Monde | 3040 | 2024-10-03 | 2026-10-09 |
| Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan Epclusa (nucleotide HCV NS5B polymerase inhibitors). - Hepatitis C | Not applicable | Enrolling by invitation | Queen Mary University of London | 318 | 2023-06-01 | 2025-11-21 |
| Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy Bevacizumab, Atezolizumab, Sofosbuvir - Liver Cancer | Phase 4 | Terminated | M.D. Anderson Cancer Center | 2 | 2023-03-17 | 2024-12-31 |
| The Efficacy of Vosevi in Treating DAA-experienced Patients Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] - Chronic Hepatitis C, Medication Reaction | Recruiting | The Third Affiliated Hospital of Guangzhou Medical University | 200 | 2023-02-28 | 2024-03-13 | |
| Elimination of Hepatitis C Virus Among Users of Substances Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa] - Hepatitis C in Substance Users | Unknown | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 1000 | 2022-11-15 | 2022-09-29 | |
| Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis Sofosbuvir/Velpatasvir + Ribavirin, Sofosbuvir/Velpatasvir/Voxilaprevir - Hepatitis C, Cirrhosis | Phase 4 | Unknown | Peking University People's Hospital | 100 | 2022-09-01 | 2022-07-21 |
| Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet - Hepatitis C, Chronic, Pregnancy; Infection | Phase 4 | Active not recruiting | Catherine Anne Chappell | 100 | 2022-04-04 | 2026-10-19 |
| Same-visit Hepatitis C Testing and Treatment (The QuickStart Study) OraQuick HCV Antibody test (OraSure Technologies, Inc), Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid), Sofosbuvir/Velpatasvir (Gilead) - Hepatitis C | Phase 4 | Unknown | Macfarlane Burnet Institute for Medical Research and Public Health Ltd | 1800 | 2022-03-09 | 2023-11-13 |
| Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] plus Ribavirin, Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] - Chronic Hepatitis C | Phase 4 | Completed | Helwan University | 281 | 2020-11-21 | 2022-09-02 |
| The Kentucky Viral Hepatitis Treatment Study Sofosbuvir/velpatasvir (Epclusa®) - Hepatitis C, Opioid-Related Disorders | Phase 4 | Completed | Jennifer Havens | 380 | 2019-09-23 | 2026-10-20 |
| Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3) sofosbubir/velpatasvir, sofosbubir/velpatasvir/voxilaprevir - Hepatitis C, Chronic | Phase 4 | Unknown | Partners in Health | 100 | 2019-08-26 | 2019-09-11 |
| Utilization of Hepatitis C Positive Kidneys in Negative Recipients Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET] - Kidney Transplant, Hepatitis C | Phase 2 / Phase 3 | Completed | Ohio State University | 54 | 2019-03-22 | 2023-09-13 |
| Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C Direct-acting antiviral agents - Hepatitis C, Chronic | Unknown | Qing XIe | 300 | 2019-03-06 | 2021-07-07 | |
| SOF/VEL±RBV: Efficacy and Safety in GT 3 and 6 HCV Patients Epclusa (sofosbuvir and velpatasvir) - Hepatitis C | Unknown | Third Affiliated Hospital, Sun Yat-Sen University | 150 | 2018-12-08 | 2021-07-02 | |
| Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection Sofosbuvir/Velpatasvir (SOF/VEL), Minimal Monitoring (MINMON) Strategy - Hepatitis C, HIV-1-infection | Phase 4 | Completed | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 400 | 2018-10-22 | 2022-02-04 |
| Influence of Cola on the Absorption of the HCV Agent Velpatasvir in Combination With PPI Omeprazole. velpatasvir - Hepatitis C, Swallowing Disorder | Phase 1 | Completed | Radboud University Medical Center | 11 | 2018-08-01 | 2020-10-19 |
| Transmission of Chronic Hepatitis C in Pregnancy SOF/VEL- sofosbuvir 400mg and velpatasvir 100mg - Hepatitis C, Pregnancy Complications | Completed | The Christ Hospital | 40 | 2018-06-08 | 2024-02-08 |
Showing 20 of 35. Sign in to see all of them.
Hepatitis C (23) · Hepatitis C, Chronic (11) · Liver Diseases (3) · Acquired Immunodeficiency Syndrome (2) · Hepatitis (2) · Hepatitis B (2) · Deglutition Disorders (1) · Drug-Related Side Effects and Adverse Reactions (1) · Fibrosis (1) · HIV Infections (1) · Hepatitis, Chronic (1) · Infections (1) · Liver Neoplasms (1) · Opioid-Related Disorders (1) · Pregnancy Complications (1)
Gilead Sciences (7) · Valme University Hospital (2) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1) · Brigham and Women's Hospital (1) · Catherine Anne Chappell (1) · Center For Hepatitis C, Atlanta, GA (1) · Duke University (1) · Getz Pharma (1) · Helwan University (1) · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (1) · Jennifer Havens (1) · Johns Hopkins University (1) · Lifespan (1) · M.D. Anderson Cancer Center (1) · Macfarlane Burnet Institute for Medical Research and Public Health Ltd (1)
United States (18) · Puerto Rico (5) · New Zealand (4) · Australia (3) · China (3) · Pakistan (2) · Spain (2) · Armenia (1) · Belgium (1) · Brazil (1) · Burma (1) · Canada (1) · Egypt (1) · Germany (1) · Italy (1)
Catherine Chappell, MD, MSc (1) · Charles Chasela, PhD (1) · Diana Brainard, M.D. (1) · Fredrick Kateera, MD, PhD (1) · Graciela Castro-Narro, MD (1) · Graham Foster, MBBS (1) · Harrys A. Torres, MD (1) · Huiying Rao, Dr. (1) · Ian Sanne, MBBCH,FRCP (1) · Jennifer Havens, PhD (1) · John Cafardi, MD (1) · John McNally (1) · John McNally, PhD (1) · Joseph Doyle, MBBS, PhD (1)
PMID 30853642, PMID 37671831, PMID 26183611, PMID 26261007, PMID 26551051, PMID 26551263, PMID 26575258, PMID 27353271, PMID 27367295, PMID 27415157, PMID 27882706, PMID 28004322, PMID 28137633, PMID 28145032, PMID 28599618, PMID 29309592, PMID 29365309, PMID 29377515, PMID 29425396, PMID 29958855, PMID 30552056, PMID 30861150, PMID 30946553, PMID 31078622, PMID 31313296, PMID 32087176, PMID 34226208, PMID 35026142, PMID 35248212, PMID 35248213, PMID 36694361, PMID 36722133, PMID 37088312, PMID 38960465, PMID 39656808, PMID 39702964, PMID 40019678, PMID 40113366, PMID 40364525, PMID 40607684, PMID 41027703, PMID 41255102, PMID 41876153
2014 (1), R01DA047952 (1), R34DA061732 (1), U01AI195193 (1), UM1AI068636 (1)